

Research Article

Antinociceptive Activity of the Chloroform Fraction of *Dioclea virgata* (Rich.) Amshoff (Fabaceae) in Mice

Vanine Gomes Mota,¹ Fabíola Lélis de Carvalho,¹ Liana Clébia Soares Lima de Morais,¹ Jnanabrata Bhattacharyya,² Reinaldo Nóbrega de Almeida,¹ and Jacicarlos Lima de Alencar¹

¹Laboratory of Pharmaceutical Technology, Center of Health Sciences, Federal University of Paraíba-UFPB, 58059-900 João Pessoa, PB, Brazil

²Department of Chemistry, University of Georgia, Athens, GA 30602, USA

Correspondence should be addressed to Jacicarlos Lima de Alencar, jacicarlos@ccm.ufpb.br

Received 4 February 2011; Revised 6 April 2011; Accepted 10 May 2011

Academic Editor: Abdel A. Abdel-Rahman

Copyright © 2011 Vanine Gomes Mota et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Acute treatment with the chloroform fraction of *Dioclea virgata* (Rich.) Amshoff (CFDv) in mice produced decreased ambulation and sedation in the behavioral pharmacological screening. Doses of 125 and 250 mg/kg CFDv decreased latency of sleep onset in the test of sleeping time potentiation. In the open field, animals treated with CFDv reduced ambulation and rearing (250 mg/kg), as well as defecation (125; 250 mg/kg). Regarding the antinociceptive activity, CFDv (125, 250, 500 mg/kg) increased latency to first writhing and decreased the number of writhings induced by acetic acid. In the formalin test, CFDv (250 mg/kg) decreased paw licking time in the first and second phases indicating antinociceptive activity that can be mediated both peripherally and at the central level. CFDv did not affect motor coordination until 120 minutes after treatment. CFDv shows psychopharmacological effects suggestive of CNS-depressant drugs with promising antinociceptive activity.

1. Introduction

Natural products, including medicinal plants, have been the primary source for obtaining new drugs with therapeutic potential throughout history. It is estimated that approximately half of the drugs in use are derived from natural products. According to the World Health Organization, poverty and lack of access to modern medicine leads from 65% to 80% of the world population in developing countries to critically depend on plants for primary health care [1].

Dioclea virgata (Rich.) Amshoff, commonly known as “cipó-pixuma” or “feijão-de-boi,” is an extremely hairy woody vine and member of the family Fabaceae (Leguminosae) [2]. Its leaves are popularly used in decoction to treat fever and malaria [3].

Although the popular uses are reported, the species is poorly scientifically investigated, being found only in one immunological study [4] with seeds of *Dioclea virgata* (Rich.) Amshoff. Furthermore, Almeida et al. (1999) [5] performed a preliminary behavior assessment in mice treated

intraperitoneally with ethanolic crude extract of *Dioclea virgata* suggesting a possible depressant action of this plant.

Other members of the family Fabaceae have already demonstrated activity on the central nervous system (CNS), such as *Clitoria ternatea*, which showed nootropic, anxiolytic, antidepressant, and anticonvulsant activities in mice and rats [6]; *Desmodium gangeticum* showed promising activity to improve memory and potential for treatment of dementia and Alzheimer's [7]; *Erythrina velutina* and *Erythrina mulungu*, popularly used in Brazil, showed CNS-depressant profile and anticonvulsant activity, possibly acting on the glycinergic system [8]; *Dioclea grandiflora* Mart ex Benth demonstrated CNS-depressant effects such as: anti-Parkinsonian [9] and antinociceptive activity in mice [10, 11].

The aim of this study was to investigate the possible psychopharmacological effects of the chloroform fraction of *Dioclea virgata* using investigative methodologies on the CNS activity in mice, in order to expand scientific knowledge about the species.

2. Material and Methods

2.1. Animals. Male and female (nulliparous and nonpregnant) 3-month-old Swiss mice (*Mus musculus*) (30–40 g body weight) were obtained from the vivarium of the Laboratory of Pharmaceutical Technology of UFPB, where they were born and bred. The animals were housed under standard laboratory conditions, with a 12-hour light/12-hour dark photoperiod, with the light period beginning at 06:00 hour. They were fed on rat chow pellets and received water *ad libitum*. The room temperature was kept at $21 \pm 1^\circ\text{C}$ and all experiments were conducted between 12:00 and 17:00 hour.

All experiments were approved by the Ethics Committee on Animal Research of LTF/UFPB, under the opinion no. 0503/07.

For each test, animals were randomly selected and equally divided into groups of 10 animals (five males and five females). All animals were taken to the testing environment at least one hour before the experiments and not tested more than once. The behavioral testing protocols were conducted under blind conditions.

2.2. Botanical Material. Leaves and branches of *Dioclea virgata* (Rich.) Amshoff were collected on 04/26/2006 in Santa Rita, Paraíba, Brazil, being the botanical identification and morphological description performed by Prof. Dr. Maria de Fátima Agra from the botany sector, Federal University of Paraíba (UFPB), and authenticated in the Herbarium Lauro Pires Xavier (JPB) UFPB, where a voucher specimen is deposited under the code AGRA 5993 JPB.

2.3. Preparation of the Chloroform Fraction of *Dioclea Virgata*. Preparation of the chloroform fraction of *Dioclea virgata* was performed by Prof. Dr. Bhattacharyya's team—LTF/UFPB. Leaves and branches of *Dioclea virgata* were dried, powdered, and extracted with methanol. The extract was concentrated in a Rotavapor apparatus, obtaining the crude methanol extract. Subsequently, it was partitioned with $\text{CHCl}_3/\text{H}_2\text{O}$ (1 : 1), obtaining the water and chloroform phases. A vacuum filtration of the latter was performed to obtain the chloroform extract free of inorganic particles. It was placed on a silica gel column and eluted with different solvents following an increasing polarity order: hexane, chloroform, ethyl acetate, and methanol. The chloroform fraction obtained by this column was used in the experiments.

2.4. Substances. Glacial acetic acid (Synth-USA), distilled water (LTF/UFPB-Brazil), sodium chloride (Merck-USA), morphine chloride (Merck-USA), ethanol (LTF/UFPB-Brazil), 37% formaldehyde (Vetec-Brazil), 2.5% formalin (LTF/UFPB-Brazil), sodium pentobarbital (Sigma-Aldrich-USA), Tween 80 (Merck-USA), and Salicylic acid (Sigma-Aldrich, USA).

Drugs were administered intraperitoneally (i.p.) at 0.1 mL/10 g of mice. Doses were prepared minutes before use, dissolved in distilled water or 0.9% saline solution. CDFV was dissolved with 5% Tween 80.

2.5. Pharmacological Evaluation

2.5.1. Behavioral Pharmacological Screening and LD_{50} Calculation. Animals were divided into groups of 10 mice and treated with different CFDv doses (between 125 and 1000 mg/kg) or vehicle intraperitoneally. Groups were observed at 30, 60, 120, 180, and 240 minutes after the respective treatments; behaviors or changes indicating pharmacological activity on the central nervous system were recorded according to the method described by Almeida et al. (1999) [5].

Assessment of possible toxic effects was carried out with the same animals used in the behavioral screening under 72 h observation to record the deaths occurrence and LD_{50} determination.

2.5.2. Pentobarbital-Induced Sleeping Time. This test evaluates the substance-induced depressive activity, since the latency reduction to sleep onset and/or additional increase in sleep time induced by pentobarbital from treatment with the test substance is indicative of CNS-depressant activity [12].

Thirty minutes after the respective treatments, animals received 40 mg/kg pentobarbital sodium (intraperitoneally) and were placed in individual boxes to record the hypnotic effect of latency and sleep time [13, 14].

2.5.3. Rota Rod Test. The method proposed by Dunham and Miya (1957) [15] involves placing mice on a rotating bar and measuring the effect of muscle relaxation or motor incoordination produced by the drug under study [16].

Animals were preselected without substance administration through a criterion of permanence in the Rota Rod machine's rotary bar (Rota-Rod Ugo Basile mod. 7750) at a constant speed of 7 revolutions per minute (7 rpm) for at least three minutes [17].

Twenty-four hours after preselection, mice deemed suitable were divided into four groups of 10 animals. Motor performance was measured as time spent walking on a rotating rod (7 rpm) during three minute trials evaluated at 30, 60, and 120 minutes after i.p. injection of CFDv (125, 250, and 500 mg/kg) or vehicle [11, 18].

2.5.4. Open-Field Test. This test evaluates the exploratory activity of animals, since their natural tendency is exploring the new environment, despite the stress and conflict that is caused [19].

The animals were submitted individually for a period of 5 minutes to an open-field test (Insight mod. EP 154C), 30 minutes after pretreatments. The parameters observed included: ambulation (recorded by the number of segments crossed by the animal with four legs), grooming, number of rearing occurrences and number of fecal masses [20]. The parameters observed were performed live.

2.5.5. Acetic Acid-Induced Abdominal Writhing. A solution of 0.8% acetic acid intraperitoneal injection in mice causes a local irritation, characterized by writhing followed by hind limbs extensions due to the nociceptor stimulation [21].

TABLE 1: Summary of multiple tests conducted with CFDv and their results.

	Methods	Results
General tests	Behavioral pharmacological screening	CNS-depressant activity
	Pentobarbital-induced sleeping time	There was no effect on total sleeping time
	Rota Rod test	Absence motor abnormality or neurotoxicity
	Open-field test	Sedative action
Specific tests (antinociceptive activity)	Acetic acid-induced abdominal writhing	Antinociceptive activity
	Formalin test	Activity may probably be mediated in the CNS level




FIGURE 1: Effect of CFDv on the latency to pentobarbital-induced sleep onset in mice. Values are expressed as mean \pm S.E.M. ($n = 10$), * $P < 0.05$ versus control group. ANOVA followed by Dunnett's Multiple Comparison Test.

Usually, drugs with analgesic properties reduce or inhibit this behavior [22].

Five groups of 10 mice received the following pretreatments by i.p. route: vehicle, 6 mg/kg morphine or CFDv (125, 250, and 500 mg/kg). Thirty minutes after initial pretreatment, animals received a solution of 0.8% acetic acid in distilled water (0.1 mL/10 g) injected i.p. and were placed in individual boxes for 20 minutes to record the latency to the first writhing and number of writhings [23].

2.5.6. Formalin Test. In this test, formalin solution is injected into the mouse's subplantar region leading to the stimulation of nociceptors [24]. The response produced by formalin is biphasic: the first phase, usually within the first 5 minutes after formalin injection, the response is neurally mediated; then there is an interphase of about 10 minutes characterized by inhibitory pain mechanisms and the second phase (15–30 minutes), and the response follows the release of inflammatory mediators [25].

Four groups of 10 mice received the following pretreatments by i.p. injection: vehicle, 250 mg/kg of CFDv, 6 mg/kg morphine, or 100 mg/kg acetylsalicylic acid (ASA). After

30 minutes, 20 μ L of 2.5% formalin solution was injected into the subplantar region of the mice's right hind paw. The parameter recorded was total time spent paw licking after formalin injection during both pain phases: first 5 minutes (neurogenic pain) and between 15 to 30 minutes (inflammatory pain) [25].

2.6. Statistical Analysis. Data were expressed by mean \pm standard error (S.E.M.) or percentage and analyzed for statistical significance using one-way analysis of variance (ANOVA) followed by Dunnett's multiple comparison test for parametric measures or Kruskal-Wallis test followed by Dunn's multiple comparison test for nonparametric measures. Tests were performed using the GraphPad Prism, version 4.0 (GraphPad Software Incorporated, San Diego, Calif, USA). The difference between groups was considered significant at $P < 0.05$.

3. Results

Table 1 shows a summary of multiple tests conducted with CFDv and their results.

3.1. Behavioral Pharmacological Screening and LD_{50} . At the dose of 125 mg/kg behavioral effects resulting from the treatment with chloroform fraction were not verified.

Animals treated with 250 and 500 mg/kg CFDv showed decreased ambulation at 30 and 60 minutes, and those receiving 500 mg/kg also showed diminished touch response.

After treatment with 1000 mg/kg mice showed decreased ambulation and reduced touch response, sedation, presence of writhing, and increased defecation up to 30 minutes. At 60 minutes of observation, animals showed reduced touch response, sedation, and diminished ambulation. Doses of 125, 250, and 500 mg/kg CFDv did not cause death of any mice. There were 10% deaths in the group of animals treated with 1000 mg/kg. From 1000 mg/kg, it was not possible to solubilize the fraction under study and the LD_{50} could not be calculated.

3.2. Pentobarbital-Induced Sleeping Time. As illustrated in Figure 1, sleep latency decreased significantly ($P < 0.05$) after CFDv administration at 125 (193.2 \pm 8.2 s) and 250 mg/kg (190.1 \pm 7.1 s) compared to the control group (236.6 \pm 8.5 s). The dose 500 mg/kg (206.5 \pm 19.7 s) did not affect significantly this parameter.




FIGURE 2: Effect of CFDv on the pentobarbital-induced sleeping time in mice. Values are expressed as mean \pm S.E.M. ($n = 10$). ANOVA followed by Dunnett's Multiple Comparison Test.




FIGURE 3: Effect of CFDv on the mice's motor coordination on the Rota Rod test after 30 minutes of doses administration. Values express the total permanence time of animals in the revolving bar. Values are expressed as mean \pm S.E.M. ($n = 10$). Kruskal-Wallis test followed by Dunn's Multiple Comparison Test.

None of the CFDv doses (125, 250, and 500 mg/kg) was able to modify significantly the sleeping time of animals compared with the control group (Figure 2).

3.3. Rota Rod Test. None of the CFDv doses was able to reduce the animals' permanence time on the revolving bar at 30 minutes after treatment (125 mg/kg: 175.2 ± 3.6 s; 250 mg/kg: 179.9 ± 0.1 s; 500 mg/kg: 163.8 ± 13.2 s) compared with the control group (179.8 ± 0.2 s). No significant impairment in motor activity was detected at 60 minutes (Control: 177.4 ± 1.7 s; 125, 250, and 500 mg/kg CFDv, 175.3 ± 3.4 s; 178.9 ± 1.1 s; 176.0 ± 3.7 s resp.) and at




FIGURE 4: Effect of CFDv on the mice's motor coordination on the Rota Rod test after 60 minutes of doses administration. Values express the total permanence time of animals in the revolving bar. Values are expressed as mean \pm S.E.M. ($n = 10$). Kruskal-Wallis test followed by Dunn's Multiple Comparison Test.




FIGURE 5: Effect of CFDv on the mice's motor coordination on the Rota Rod test after 120 minutes of doses administration. Values express the total permanence time of animals in the revolving bar. Values are expressed as mean \pm S.E.M. ($n = 10$). Kruskal-Wallis test followed by Dunn's Multiple Comparison Test.

120 minutes (125 mg/kg: 177.5 ± 1.9 s; 250 mg/kg: 171.8 ± 7.3 ; 500 mg/kg: 162.3 ± 14.7 ; Control: 178.5 ± 1.0 s) after treatment with CFDv (Figures 3, 4, and 5).

3.4. Open-Field Test. Animals receiving 250 mg/kg CFDv showed reduction in ambulation (94.6 ± 9.1) compared to the control group (140.8 ± 14.0) (Figure 6).

Grooming behavior in the groups treated with CFDv (125, 250 and 500 mg/kg) was not changed (15.3 ± 5.8 , 7.8 ± 2.4 and 15.1 ± 5.6 seconds, resp.) compared to the control group (3.1 ± 1.4 seconds).




FIGURE 6: Effect of CFDv on the ambulation in mice subjected to the open field apparatus for 5 minutes. Values are expressed as mean \pm S.E.M. ($n = 10$), * $P < 0.05$ versus control group. ANOVA followed by Dunnett's Multiple Comparison Test.




FIGURE 7: Effect of CFDv on the rearing in mice subjected to the open field apparatus for 5 minutes. Values are expressed as mean \pm S.E.M. ($n = 10$), * $P < 0.05$ versus control group. ANOVA followed by Dunnett's Multiple Comparison Test.

Only animals treated with 250 mg/kg CFDv (25.8 ± 4.2) decreased significantly the number of rearing occurrences compared to the control (43.4 ± 4.7) (Figure 7).

Furthermore, the doses of 125 mg/kg (0.3 ± 0.1) or 250 mg/kg (0.2 ± 0.1) significantly reduced the number of fecal masses compared to the control (1.4 ± 0.2) whilst the one of 500 mg/kg (0.8 ± 0.3) did not (Figure 8).

3.5. Acetic Acid-Induced Abdominal Writhing. In all groups treated with CFDv (125 mg/kg: 722.5 ± 131.0 s; 250 mg/kg: 999.6 ± 106.1 s; 500 mg/kg: 890.3 ± 79.47 s), there was an




FIGURE 8: Effect of CFDv on the defecation (number of fecal masses) in mice subjected to the open field apparatus for 5 minutes. Values are expressed as mean \pm S.E.M. ($n = 10$), * $P < 0.05$, ** $P < 0.01$ versus control group. Kruskal-Wallis test followed by Dunn's Multiple Comparison Test.




FIGURE 9: Effect of CFDv on the latency on acetic acid-induced abdominal writhings in mice. Values are expressed as mean \pm S.E.M. ($n = 10$), * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$ versus control group. Kruskal-Wallis test followed by Dunn's Multiple Comparison Test.

increased latency to the first writhing appearance compared to the control group (278.2 ± 25.4 s), similar to morphine (1127.0 ± 73.5 s) (Figure 9).

As shown in Figure 10, there was a decrease in the number of writhings in all groups for which the CFDv was administered (125 mg/kg: 8.7 ± 2.7 ; 250 mg/kg: 3.6 ± 1.8 ; 500 mg/kg: 5.3 ± 1.7) compared to control (24.3 ± 2.8).




FIGURE 10: Effect of CFDv on the number of writhings on acetic acid-induced abdominal writhings in mice. Values are expressed as mean \pm S.E.M. ($n = 10$), * $P < 0.05$, *** $P < 0.001$ versus control group. Kruskal-Wallis test followed by Dunn's Multiple Comparison Test.




FIGURE 11: Effect of CFDv on 1st phase on formalin-induced licking in mice. Values are expressed as mean \pm S.E.M. ($n = 10$), ** $P < 0.01$ versus control group. ANOVA followed by Dunnett's Multiple Comparison Test.

3.6. *Formalin Test.* Mice treated with 250 mg/kg CFDv showed significant reduction of paw licking time in the first phase, with 60.9 ± 9.8 seconds compared to control 91.1 ± 6.8 (Figure 11). Thus, we obtained a result similar to that of the standard group treated with morphine (37.5 ± 4.8). In the group treated with 100 mg/kg ASA, there was no significant reduction in the parameter evaluated (81.7 ± 1.5).




FIGURE 12: Effect of CFDv on 2nd phase on formalin-induced licking in mice. Values are expressed as mean \pm S.E.M. ($n = 10$), ** $P < 0.01$ versus control group. ANOVA followed by Dunnett's Multiple Comparison Test.

As the result shown in Figure 12, CFDv at 250 mg/kg (12.3 ± 10.4 s) reduced the paw licking time during the second phase of the formalin test when compared with the control group (213.3 ± 51.6 s), morphine (33.7 ± 8.1 s) and ASA (89.7 ± 11.5 s).

4. Discussion

This work consisted of investigating the CFDv antinociceptive activity. To observe the suggestive effect on the central nervous system (CNS) and/or autonomic nervous system (ANS) and possible toxic effects, we performed a behavioral pharmacological screening with CFDv at the doses of 125, 250, 500 and 1000 mg/kg, administered intraperitoneally in mice [26].

Effects observed on the doses of 250, 500, and 1000 mg/kg suggested a possible CNS-depressant activity, for example, reduced ambulation, impaired touch response and sedation [5, 27, 28].

These results are similar to the ones reported by Almeida et al. [5] who observed CNS-depressant activity in mice subjected to behavioral screening treated with crude ethanol extract of *Dioclea virgata* (Rich.) Amshoff.

Pentobarbital-induced sleeping time, Rota Rod, and open-field tests were chosen as general tests to investigate the possible CFDv's psychodepressant activity observed in the screening.

Through the test for sleeping time, potentiation induced by sodium pentobarbital is possible to assess whether the tested substance has neurosedative action or a hypnotic profile [29].

Pentobarbital, as a barbiturate, acts primarily at the synapses where the neurotransmission is mediated by GABA in type-A GABAergic receptors. These receptors are characterized by being ion channels permeable to chloride, in which

barbiturates act by increasing conductance to this ion and thus enhancing the inhibitory GABA effect that is the main central inhibitory neurotransmitter [30].

It is worth mentioning that the test for pentobarbital-induced sleeping potentiation is not a specific test, since drugs devoid of central action, such as those that decrease oxygen uptake by tissues or even those that cause vasodilation or vasoconstriction, potentiate the sleeping time by interfering with the pentobarbital biotransformation in the cytochrome P450 complex, and thus may produce the same actions of CNS-depressant drugs [31, 32].

Latency decrease was observed in this test period considered between the pentobarbital administration and the hypnotic effect onset [33], being characterized by loss of righting reflex in animals treated with 125 and 250 mg/kg CFDv. However, the fraction studied did not affect the sleeping time when compared to the control group.

A possible myorelaxing activity as well as the animal's motor coordination was evaluated in the test using the Rota Rod through the total time of permanence in the rotating bar [34]. The lack of motor coordination in the Rota Rod test is a characteristic of pharmacological agents, such as skeletal muscle relaxants or drugs that reduce the CNS activity, such as neuroleptics, anxiolytics, sedatives, and hypnotics [35, 36].

It is noteworthy, however, that the Rota Rod test is a nonspecific method, since it measures neurological effects, stimulants, and depressants on motor coordination indiscriminately to which is also assigned the term neurotoxicity [37]. As no significant reduction in animals' permanence time in the revolving bar at 30, 60, and 120 minutes after the three doses studied (125, 250, and 500 mg/kg CFDv) has occurred, it may indicate that the CFDv treatment does not interfere with motor coordination, thus ruling out a muscle relaxant effect or even a neurotoxicity that is common to some drugs with CNS-depressant profile.

The open-field test, originally described by Hall in 1934 for studying emotionality in rats, is a method used to assess exploratory behavior, reaction to the new, anxiety, memory, and stimulating activity, in addition to sedation and locomotor activity [20, 38]. Animals subjected to open-field test showed decrease in ambulation as well as in the number of rearing times when receiving 250 mg/kg CFDv. There was also defecation reduction for animals treated with 125 and 250 mg/kg CFDv, but there was no effect with the 500 mg/kg dose. Grooming was the only parameter that did not change with the three doses tested.

The inhibition of ambulation and rearing is related to drugs with sedative action [20, 39]. Research shows that a high level of emotionality is related to increases in defecation; anxiolytic drugs reduce defecation [40, 41]. However, further studies to investigate whether CFDv caused changes in smooth muscle activity of the gastrointestinal system would be needed. It cannot be concluded that CFDv reduced defecation by reducing anxiety. According to Shaw et al. 2007 [41], grooming usually increases in situations of fear or anxiety in rodents being an adaptation index to a stressful situation. Anxiolytic drugs reduce this behavior in the open field test.

To analyze the possible CFDv antinociceptive activity, two behavioral methods were used to induce nociception: the acetic acid-induced writhing test, which produces chemical noxious stimulation in the periphery system with a medullary component, and the formalin test, animal model with nociceptors stimulation that results in a pain-indicative behavior biphasic model.

The acetic acid-induced abdominal writhing test, an animal model for nociceptor stimulation to screening drugs with analgesic activity based on irritation caused after intraperitoneal injection of acetic acid solution. This injection can produce a peritoneal inflammation characterized by contractions of abdominal muscles followed by hind limbs extension [21, 23].

Although simple, fast, and reliable to assess the antinociceptive activity of substances [42], is a low specific method since it is sensitive to nonsteroidal anti-inflammatory drugs, narcotics and other centrally acting drugs, anticholinergics, and antihistamines [43, 44].

Treatment with CFDv caused increased latency to the first writhing in mice and reduction in the number of writhings in the three experimental groups, similar to the standard group treated with morphine; being observed that changes in these parameters were not dose-dependent.

These results are similar to those reported by Batista et al. (1995) [10] with aqueous fraction and flavonoid dioclein obtained from the ethanol extract of *Dioclea grandiflora*, as well as those of Sá et al. [11] conducted with *Dioclea grandiflora* seed pod. Among other plant species of the family Fabaceae evaluated in the acetic acid methodology, it may be mentioned that the extract of *Erythrina velutina* and *Erythrina mulungu*, the aqueous extract of *Desmodium gangeticum* DC, as well as the extract and some fractions from *Erythrina crista-galli*, reduced the number of writhings in rodent studies [8, 45, 46].

In an attempt to better characterize the CFDv activity found in the acetic acid-induced writhing test, the formalin model was employed and CFDv injected at a dose of 250 mg/kg. Formalin produced a different biphasic response where analgesics may act differently in the first and second trial phases [47]. The first phase of the formalin model lasts a few minutes and begins immediately after the injection of formalin in the plantar surface of the animal and is due to release of the substance P and direct chemical stimulation of afferents, especially C fibers [48, 49]. It reflects the neurogenic component of nociception being sensitive to drugs that act primarily on the central system, such as opioids [50].

Between the first and second phases of the formalin test, there is a rest period called the "interface" which occurs due to an activation of inhibitory processes GABA-mediated mechanisms, since the type-A GABAergic agonists inhibits the decrease of pain manifestations during this period [51, 52].

The inflammatory component of the nociceptive response (second phase) starts after 10 to 15 minutes of "interface" and is the result of inflammatory mediator release such as bradykinin, histamine, sympathomimetic amines, tumoral- α necrosis factor, and interleukins [50] or a facilitation of spinal synaptic transmission [53, 54].

It is interesting to consider that centrally acting drugs such as opioids inhibit both formalin test phases. Nevertheless, peripheral acting drugs such as anti-inflammatory drugs are effective only in the second phase [49, 55]. According to Hunskaar and Hole [25], the second phase is sensitive to both NSAIDs and corticosteroids.

Similar to the results of Sá et al. (2010) [11] with *Dioclea grandiflora*, CFDv produced nociceptive response reduction in both formalin test phases, similarly to morphine and other centrally acting analgesic drugs, which are widely effective in preventing the pain formalin-induced pain in both testing phases [44], thus indicating that the CFDv antinociceptive effect presents a central component and a possible anti-inflammatory activity. As expected, the analgesic effect produced by ASA was evident only in the second phase of this test [56].

5. Conclusions

Data presented in this study showed that CFDv exerts current antinociceptive activity with little or no effects and no dose-response relationships in tests for CNS depression or sedation. The reduction in pain responsiveness seemed similar to that morphine dose-induced, indicating that this activity may probably be mediated in the CNS level. In addition, CFDv did not promote muscle relaxation and incoordination, or neurotoxicity by any alteration in the permanence time in the Rota Rod test's rotating bar. However, further studies are necessary to elucidate the mechanism behind the observed effects.

Acknowledgments

The authors are grateful to FAPSEQ-PB and Prof. Dr. Maria de Fátima Agra, botany sector, Federal University of Paraíba PB-João Pessoa, Brazil, for botanical identification and morphological description of *Dioclea virgata* (Rich.) Amshoff.

References

- [1] A. G. Parker, G. G. Peraza, J. Sena et al., "Antinociceptive effects of the aqueous extract of *Brugmansia suaveolens* flowers in Mice," *Biological Research for Nursing*, vol. 8, no. 3, pp. 234–239, 2007.
- [2] M. F. Silva, *In Nomes Populares das Leguminosas do Brasil*, EDUA/IMPA/FAPEAM, Manaus, Brazil, 2004.
- [3] M. F. Agra, P. F. De Freitas, and J. M. Barbosa-Filho, "Synopsis of the plants known as medicinal and poisonous in northeast of Brazil," *Brazilian Journal of Pharmacognosy*, vol. 17, no. 1, pp. 114–140, 2007.
- [4] M. Barral-Netto, S. B. Santos, A. Barral et al., "Human lymphocyte stimulation by legume lectins from the diocleae tribe," *Immunological Investigations*, vol. 21, no. 4, pp. 297–303, 1992.
- [5] R. N. Almeida, A. C. G. M. Falcão, R. S. T. Diniz et al., "Metodologia para avaliação de plantas com atividade no sistema nervoso central e alguns dados experimentais," *Revista Brasileira de Farmacia*, vol. 80, no. 3-4, pp. 72–76, 1999.
- [6] N. N. Jain, C. C. Ohal, S. K. Shroff et al., "*Clitoria ternatea* and the CNS," *Pharmacology Biochemistry and Behavior*, vol. 75, no. 3, pp. 529–536, 2003.
- [7] H. Joshi and M. Parle, "Antiamnesic effects of *Desmodium gangeticum* in mice," *Yakugaku Zasshi*, vol. 126, no. 9, pp. 795–804, 2006.
- [8] S. M. M. Vasconcelos, G. R. Oliveira, M. M. Carvalho et al., "Antinociceptive activities of the hydroalcoholic extracts from *Erythrina velutina* and *Erythrina mulungu* in mice," *Biological and Pharmaceutical Bulletin*, vol. 26, no. 7, pp. 946–949, 2003.
- [9] L. C. S. L. Morais, *Possível influência dos tratamentos com extratos vegetais em sintomas extrapiramidais induzidos farmacologicamente em camundongos*, Doutora em Produtos Naturais—Farmacologia, Universidade Federal da Paraíba, João Pessoa, Brazil, 2005.
- [10] J. S. Batista, R. N. Almeida, and J. Bhattacharyya, "Analgesic effect of *Dioclea grandiflora* constituents in rodents," *Journal of Ethnopharmacology*, vol. 45, no. 3, pp. 207–210, 1995.
- [11] R. C. S. Sá, L. E. G. Oliveira, F. F. F. Nóbrega et al., "Antinociceptive and toxicological effects of *Dioclea grandiflora* seed pod in mice," *Journal of Biomedicine and Biotechnology*, vol. 2010, Article ID 606748, 6 pages, 2010.
- [12] B. Adzu, S. Amos, S. Dzarma et al., "Effect of *Zizyphus spinachristi* Willd aqueous extract on the central nervous system in mice," *Journal of Ethnopharmacology*, vol. 79, no. 1, pp. 13–16, 2002.
- [13] E. A. Carlini, J. D. P. Constar, A. R. Silva-Filho et al., "Pharmacology Of lemon-grass (*Cymbopogon citrates* Stapf.): effects of teas prepared from leaves on laboratory-animals," *Journal of Ethnopharmacology*, vol. 17, no. 1, pp. 37–64, 1986.
- [14] R. Mattei, R. F. Dias, E. B. Espínola, E. A. Carlini, and S. B. M. Barros, "Guaraná (*Paullinia cupana*): toxic behavioral effects in laboratory animals and antioxidant activity in vitro," *Journal of Ethnopharmacology*, vol. 60, no. 2, pp. 111–116, 1998.
- [15] N. W. Dunham and T. S. A. Miya, "A note on a simple apparatus for detecting neurological deficit in rats and mice," *Journal of the American Pharmaceutical Association*, vol. 46, no. 3, pp. 208–209, 1957.
- [16] E. A. Carlini and V. Burgos, "Screening farmacológico de ansiolíticos: metodologia Laboratorial e comparação entre o diazepam e o clorbenzapam," *Revista da Associação Brasileira de Psiquiatria*, vol. 1, pp. 25–31, 1979.
- [17] F. R. Mendes, R. Mattei, and E. L. A. Carlini, "Activity of *Hypericum brasiliense* and *Hypericum cordatum* on the central nervous system in rodents," *Fitoterapia*, vol. 73, no. 6, pp. 462–471, 2002.
- [18] L. C. S. L. Morais, L. J. Quintans-Júnior, C. I. F. Franco et al., "Antiparkinsonian-like effects of *Plumbago scandens* on tremorine-induced tremors methodology," *Pharmacology Biochemistry and Behavior*, vol. 79, no. 4, pp. 745–749, 2004.
- [19] K. C. Montgomery, "The relationship between fear induced by novel stimulation an exploration behavior," *Journal of Comparative and Physiological Psychology*, vol. 48, no. 2, pp. 254–260, 1955.
- [20] L. Prut and C. Belzung, "The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review," *European Journal of Pharmacology*, vol. 463, no. 1–3, pp. 3–33, 2003.
- [21] R. Koster, M. Anderson, and E. J. Debber, "Acetic acid for analgesic screening," *Federation Proceedings*, vol. 18, pp. 418–420, 1959.
- [22] H. O. J. Collier, L. C. Dinneen, C. A. Johnson et al., "The abdominal constriction response and its suppression by

- analgesic drugs in the mouse," *British Journal of Pharmacology*, vol. 32, no. 2, pp. 295–310, 1968.
- [23] G. M. Nardi, S. Dalbó, F. D. Monache et al., "Antinociceptive effect of *Croton celtidifolius* Baill (Euphorbiaceae)," *Journal of Ethnopharmacology*, vol. 107, no. 1, pp. 73–78, 2006.
- [24] M. M. Souza, A. Madeira, C. Berti, R. Krogh, R. A. Yunes, and V. Cechinel-Filho, "Antinociceptive properties of the methanolic extract obtained from *Ipomoea pes-caprae* (L.) R. Br.," *Journal of Ethnopharmacology*, vol. 69, no. 1, pp. 85–90, 2000.
- [25] S. Hunskaar and K. Hole, "The formalin test in mice: dissociation between inflammatory and non-inflammatory pain," *Pain*, vol. 30, no. 1, pp. 103–114, 1987.
- [26] R. N. Almeida, *Psicofarmacologia: Fundamentos Práticos*, Guanabara Koogan, Rio de Janeiro, Brazil, 1st edition, 2006.
- [27] A. Fernández-Guasti, A. Ferreira, and O. Picazo, "Diazepam, but not buspirone, induces similar anxiolytic-like actions in lactating and ovariectomized wistar rats," *Pharmacology Biochemistry and Behavior*, vol. 70, no. 1, pp. 85–93, 2001.
- [28] A. Argal and A. K. Pathak, "CNS activity of *Calotropis gigantea* roots," *Journal of Ethnopharmacology*, vol. 106, no. 1, pp. 142–145, 2006.
- [29] F. A. Santos, V. S. N. Rao, and E. R. Silveira, "Studies on the neuropharmacological effects of *Psidium guyanensis* and *Psidium pohlium* essential oils," *Phytotherapy Research*, vol. 10, no. 8, pp. 655–658, 1996.
- [30] D. S. Charney, S. J. Mihic, and R. A. Harris, "Hipnóticos e sedativos," in *As Bases Farmacológicas da Terapêutica*, L. S. Goodman and A. Gilman, Eds., chapter 17, pp. 303–324, McGraw-Hill, Rio de Janeiro, Brazil, 10th edition, 2003.
- [31] T. D. Goloubkova, E. Heckler, S. M. K. Rates, J. A. P. Henriques, and A. T. Henriques, "Inhibition of cytochrome P450-dependent monooxygenases by an alkaloid fraction from *Helietta apiculata* markedly potentiate the hypnotic action of pentobarbital," *Journal of Ethnopharmacology*, vol. 60, no. 2, pp. 141–148, 1998.
- [32] M. A. Gyamfi, N. Hokama, K. Oppong-Boachie et al., "Inhibitory effects of the medicinal herb, *Thonningia sanguinea*, on liver drug metabolizing enzymes of rats," *Human and Experimental Toxicology*, vol. 19, no. 11, pp. 623–631, 2000.
- [33] S. A. Neves, A. L. P. Freitas, B. W. Sousa et al., "Antinociceptive properties in mice of a lectin isolated from the marine alga *Amansia multifida* Lamouroux," *Brazilian Journal of Medical and Biological Research*, vol. 40, no. 1, pp. 127–134, 2007.
- [34] A. Capasso, V. De Feo, F. De Simone, and L. Sorrentino, "Pharmacological effects of aqueous extract from *Valeriana adscendens*," *Phytotherapy Research*, vol. 10, no. 4, pp. 309–312, 1996.
- [35] T. Sen and A. K. Nag Chaudhuri, "Studies on the neuropharmacological aspects of *Pluchea indica* root extract," *Phytotherapy Research*, vol. 6, no. 4, pp. 175–179, 1992.
- [36] A. M. Pultrini, L. A. Galindo, and M. Costa, "Effects of the essential oil from *Citrus aurantium* L. in experimental anxiety models in mice," *Life Sciences*, vol. 78, no. 15, pp. 1720–1725, 2006.
- [37] D. P. De Sousa, F. F. F. Nóbrega, F. S. Claudino, R. N. De Almeida, J. R. Leite, and R. Mattei, "Pharmacological effects of the monoterpene α , β -epoxy-carvone in mice," *Brazilian Journal of Pharmacognosy*, vol. 17, no. 2, pp. 170–175, 2007.
- [38] A. Ennaceur, S. Michalikova, and P. L. Chazot, "Models of anxiety: responses of rats to novelty in an open space and an enclosed space," *Behavioural Brain Research*, vol. 171, no. 1, pp. 26–49, 2006.
- [39] F. Huang, Y. Xiong, L. Xu, S. Ma, and C. Dou, "Sedative and hypnotic activities of the ethanol fraction from *Fructus Schisandrae* in mice and rats," *Journal of Ethnopharmacology*, vol. 110, no. 3, pp. 471–475, 2007.
- [40] M. Angrini, J. C. Leslie, and R. A. Shephard, "Effects of propranolol, buspirone, pCPA, reserpine, and chlordiazepoxide on open-field behaviour," *Pharmacology, Biochemistry and Behavior*, vol. 59, no. 2, pp. 387–397, 1998.
- [41] D. Shaw, J. M. Annett, B. Doherty, and J. C. Leslie, "Anxiolytic effects of lavender oil inhalation on open-field behaviour in rats," *Phytomedicine*, vol. 14, no. 9, pp. 613–620, 2007.
- [42] U. A. Shinde, A. S. Phadke, A. M. Nair, A. A. Mungantiwar, V. J. Dikshit, and M. N. Saraf, "Studies on the anti-inflammatory and analgesic activity of *Cedrus deodara* (Roxb.) Loud. wood oil," *Journal of Ethnopharmacology*, vol. 65, no. 1, pp. 21–27, 1999.
- [43] M. S. Alexandre-Moreira, M. R. Piuvezam, C. C. Araújo, and G. Thomas, "Studies on the anti-inflammatory and analgesic activity of *Curatella americana* L.," *Journal of Ethnopharmacology*, vol. 67, no. 2, pp. 171–177, 1999.
- [44] G. N. T. Bastos, A. R. S. Santos, V. M. M. Ferreira et al., "Antinociceptive effect of the aqueous extract obtained from roots of *Physalis angulata* L. on mice," *Journal of Ethnopharmacology*, vol. 103, no. 2, pp. 241–245, 2006.
- [45] S. Jabbar, M. T. H. Khan, and M. S. Choudhuri, "The effects of aqueous extracts of *Desmodium gangeticum* DC. (Leguminosae) on the central nervous system," *Pharmazie*, vol. 56, no. 6, pp. 506–508, 2001.
- [46] L. G. O. Fischer, R. Leitão, S. R. Etcheverry et al., "Analgesic properties of extracts and fractions from *Erythrina crista-galli* (Fabaceae) leaves," *Natural Product Research*, vol. 21, no. 8, pp. 759–766, 2007.
- [47] K. Morteza-Semnani, M. Saeedi, M. Hamidian, H. Vafamehr, and A. R. Dehpour, "Anti-inflammatory, analgesic activity and acute toxicity of *Glaucium grandiflorum* extract," *Journal of Ethnopharmacology*, vol. 80, no. 2-3, pp. 181–186, 2002.
- [48] C. G. Heapy, A. Jamieson, and N. J. W. Russel, "Afferent C-fibre and A- δ activity in models of inflammation," *British Journal of Pharmacology*, vol. 90, p. 164, 1987.
- [49] M. Shibata, T. Ohkubo, H. Takahashi, and R. Inoki, "Modified formalin test: characteristic biphasic pain response," *Pain*, vol. 38, no. 3, pp. 347–352, 1989.
- [50] A. A. Ferreira, F. A. Amaral, I. D. G. Duarte et al., "Antinociceptive effect from *Ipomoea cairica* extract," *Journal of Ethnopharmacology*, vol. 105, no. 1-2, pp. 148–153, 2006.
- [51] J. L. Henry, K. Yashpal, G. M. Pitcher, and T. J. Coderre, "Physiological evidence that the "interphase" in the formalin test is due to active inhibition," *Pain*, vol. 82, no. 1, pp. 57–63, 1999.
- [52] S. R. S. Lira, *Efeitos farmacológicos do extrato etanólico de Combretum leprosum Mart. & Eicher sobre o sistema nervoso central*, Mestrado em Produtos Naturais e Sintéticos Bioativos, Universidade Federal da Paraíba, João Pessoa, Brazil, 2001.
- [53] A. Tjolsen, O. G. Berge, S. Hunskaar, J. H. Rosland, and K. Hole, "The formalin test: an evaluation of the method," *Pain*, vol. 51, no. 1, pp. 5–17, 1992.
- [54] D. S. França, A. L. S. Souza, K. R. Almeida, S. S. Dolabella, C. Martinelli, and M. M. Coelho, "B vitamins induce an antinociceptive effect in the acetic acid and formaldehyde models of nociception in mice," *European Journal of Pharmacology*, vol. 421, no. 3, pp. 157–164, 2001.

- [55] J. Miño, C. Acevedo, V. Moscatelli, G. Ferraro, and O. Hnatyszyn, "Antinociceptive effect of the aqueous extract of *Balbisia calycina*," *Journal of Ethnopharmacology*, vol. 79, no. 2, pp. 179–182, 2002.
- [56] C. Rujjanawate, D. Kanjanapothi, and A. Panthong, "Pharmacological effect and toxicity of alkaloids from *Gelsemium elegans* Benth," *Journal of Ethnopharmacology*, vol. 89, no. 1, pp. 91–95, 2003.